NEW YORK (GenomeWeb) – Horizon Discovery Group announced this week a $1.2 million master services agreement with an unnamed "major global diagnostic development company and a US biopharmaceutical company" to support the development of companion diagnostics for genetically targeted oncology therapies. In the first project covered by the agreement, Horizon will generate genetically defined cell lines and related gDNA and formalin-fixed, paraffin-embedded standards. Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.